Mardi, 22 Mai 2018
Dernières nouvelles
Principale » The Inovio Pharmaceuticals (INO) Getting Positive Press Coverage, Analysis Finds

The Inovio Pharmaceuticals (INO) Getting Positive Press Coverage, Analysis Finds

14 Juin 2017

(NASDAQ:INO)'s stock was 16.71%. $16.17's average target is 97.68% above currents $8.18 stock price.

10/04/2016 - Brean Capital began new coverage on Inovio Pharmaceuticals, Inc. giving the company a " rating.

Research professionals at H.C. Wainwright now has a $13.0000 PT on Inovio Pharmaceuticals (NASDAQ:INO).

05/24/2017 - Inovio Pharmaceuticals, Inc. had its " rating reiterated by analysts at Maxim Group. The rating was upgraded by PiperJaffray to "Overweight" on Thursday, June 8. The company was maintained on Tuesday, January 5 by Maxim Group. As per Thursday, June 8, the company rating was upgraded by PiperJaffray. The market capitalization of the company is at $600.64 Million.

Over the past 50 days, Inovio Pharmaceuticals, Inc. stock's -17.04% off of the high and 37.02% removed from the low. Consensus earnings estimates are far from ideal, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Wednesday, May 10th. The analysts estimated EPS for the higher end at -0.01 and lower end at -0.37 while the year ago reported earnings per share was -0.15. (INO) is -0.31 while the analysts predicted the EPS of the stock to be -0.31 suggesting the company fell short of the analysts' expectations. Inovio Pharmaceuticals had a negative net margin of 199.99% and a negative return on equity of 39.93%. The business's revenue for the quarter was up 28.4% compared to the same quarter previous year.

Is James Comey Baiting Donald Trump into Making a Mistake?
Earlier Mr Trump had his silence on Twitter, tweeting he'd been vindicated and derided Comey as a "leaker". Comey had also testified that, at a private dinner in January, Trump had asked for his personal loyalty.

Earnings per share (EPS) is the portion of a company's profit allocated to each outstanding share of common stock. Analysts anticipate that Inovio Pharmaceuticals will post ($1.10) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: "Inovio Pharmaceuticals, Inc". American International Group Inc. now owns 40,856 shares of the biopharmaceutical company's stock valued at $270,000 after buying an additional 2,695 shares in the last quarter. If you are reading this news story on another website, it was stolen and reposted in violation of United States and global copyright & trademark laws. The stock was sold at an average price of $6.54, for a total transaction of $962,557.20. Following the completion of the sale, the director now directly owns 740,956 shares of the company's stock, valued at $5,927,648. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jong Joseph Kim sold 147,180 shares of Inovio Pharmaceuticals stock in a transaction dated Friday, March 31st.

INO has a 1-year high price of $ 11.61 and 1-year low price of $5.83. The stock was acquired at an average cost of $6.25 per share, with a total value of $133,125.00. The disclosure for this sale can be found here.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Inovio Pharmaceuticals by 7.9% in the first quarter. Bank of New York Mellon Corp raised its position in Inovio Pharmaceuticals by 3.6% in the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company's stock worth $879,000 after buying an additional 69,068 shares during the period. Finally, Stoneridge Investment Partners LLC raised its position in Inovio Pharmaceuticals by 0.8% in the first quarter. Finally, Stoneridge Investment Partners LLC raised its stake in shares of Inovio Pharmaceuticals by 0.8% in the first quarter.

Inovio Pharmaceuticals, Inc.is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases.